Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Audrey A M Vollebregt

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Expert Opinion on Pharmacotherapy|September 27, 2012
Treatment options for lysosomal storage disorders: developing insightsCarin M van Gelder, Audrey A M Vollebregt, Iris Plug, et al.
The Journal of Pediatrics|May 14, 2022
Effect of Anti-Iduronate 2-Sulfatase Antibodies in Patients with Mucopolysaccharidosis Type II Treated with Enzyme Replacement TherapyAudrey A M Vollebregt, Marianne Hoogeveen-Westerveld, George J Ruijter, et al.
Developmental Medicine and Child Neurology|May 26, 2017
Genotype-phenotype relationship in mucopolysaccharidosis II: predictive power of IDS variants for the neuronopathic phenotypeAudrey A M Vollebregt, Marianne Hoogeveen-Westerveld, Marian A Kroos, et al.
Journal of Inherited Metabolic Disease|December 17, 2020
Can serial cerebral MRIs predict the neuronopathic phenotype of MPS II?Audrey A M Vollebregt, Berendine J Ebbink, Dimitris Rizopoulos, et al.
Molecular Genetics and Metabolism|March 26, 2013
Up to five years experience with 11 mucopolysaccharidosis type VI patientsMarion M M G Brands, Esmee Oussoren, George J G Ruijter, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Expert Opinion on Pharmacotherapy|September 27, 2012
Treatment options for lysosomal storage disorders: developing insightsCarin M van Gelder, Audrey A M Vollebregt, Iris Plug, et al.
The Journal of Pediatrics|May 14, 2022
Effect of Anti-Iduronate 2-Sulfatase Antibodies in Patients with Mucopolysaccharidosis Type II Treated with Enzyme Replacement TherapyAudrey A M Vollebregt, Marianne Hoogeveen-Westerveld, George J Ruijter, et al.
Developmental Medicine and Child Neurology|May 26, 2017
Genotype-phenotype relationship in mucopolysaccharidosis II: predictive power of IDS variants for the neuronopathic phenotypeAudrey A M Vollebregt, Marianne Hoogeveen-Westerveld, Marian A Kroos, et al.
Journal of Inherited Metabolic Disease|December 17, 2020
Can serial cerebral MRIs predict the neuronopathic phenotype of MPS II?Audrey A M Vollebregt, Berendine J Ebbink, Dimitris Rizopoulos, et al.
Molecular Genetics and Metabolism|March 26, 2013
Up to five years experience with 11 mucopolysaccharidosis type VI patientsMarion M M G Brands, Esmee Oussoren, George J G Ruijter, et al.
Pageof 1